Supriya Lifescience Reports 31% Year-on-Year Revenue Growth in Q1 FY27

Revenue rises to Rs 189.75 crore as Asia becomes the company’s largest market during the quarter

Supriya Lifescience Ltd., a cGMP-compliant active pharmaceutical ingredient (API) manufacturer with operations in more than 120 countries, has announced its unaudited financial results for the first quarter of FY27. The company reported 30.8% year-on-year revenue growth, with revenue increasing to Rs 189.75 crore from Rs 145.07 crore in the corresponding quarter of the previous fiscal.

The quarter also saw continued growth in exports, expansion of the company’s product portfolio, progress in manufacturing capacity and advancement of its research and development initiatives.

Q1 FY27 financial performance

For the quarter ended Q1 FY27, Supriya Lifescience reported:

Therapeutic segments and regional performance

The Anesthetic segment remained the company's largest therapeutic contributor, accounting for 48% of revenue in Q1 FY27, compared with 53% in Q1 FY26.

The Vitamins segment contributed 17% of revenue, up from 11% in the corresponding quarter last year.

Regionally, Asia became the company's largest market, contributing 39% of revenue, compared with 32% in Q1 FY26.

Other regional contributions included:

• Europe: 35%
• LATAM: 20%
• North America: 3%
• Other markets: 3%

Exports accounted for 81% of total revenue during the quarter.

Product pipeline and manufacturing updates

During Q1 FY27, the company reported continued progress across its product portfolio.

The Cardiovascular product launched in Q3 FY26 contributed revenue from Q4 FY26, while the ADHD product recorded increased demand from LATAM and Europe and continued to scale up.

The Liquid Anesthetic product has been commercialised, with regular monthly supplies underway.

For FY27, the company plans to introduce approximately two launches each in the Anesthetic and ADHD segments.

Capacity expansion and R&D

Capacity utilisation stood at 70% in Q1 FY27, compared with 74% in FY26 and 70% in FY25.

The company currently has a total reactor capacity of 932 KLPD across its manufacturing facilities.

At its Ambernath facility, finished dosage manufacturing capabilities covering tablets, capsules, liquids, nasal, inhalation and injections have been commissioned. Validation and registration batches are currently in progress for dossier submissions.

Supriya Lifescience also continues to strengthen its research and development capabilities with more than 68 scientists focused primarily on API and formulation process development.

The company has established two R&D centres at Ambernath and Lote and continues efforts to add 3–4 products annually.

Management comment

Commenting on the results, Dr. Satish Wagh, Executive Chairman and Whole-Time Director, Supriya Lifescience Ltd., said, “Q1 FY27 reflects continued momentum in our core business, supported by strong revenue growth and a diversified presence across global markets. Our focus remains on expanding our product portfolio, strengthening manufacturing and R&D capabilities, and scaling new products across key therapeutic segments. With a strong export-oriented business, continued investments in capacity and innovation, and a growing pipeline across Anesthetic and ADHD, we remain focused on building sustainable long-term growth.”